Google launches new health business

Google has announced the creation of a new company that will focus on health and well-being, in particular the challenge of ageing and associated diseases.
The firm, named Calico - an abbreviation for the “California Life Company” - will be led and invested in by Arthur Levinson, chairman and former chief executive of Genentech and current chairman of Google's rival internet firm Apple.
Announcing this new investment Larry Page, Google’s chief executive, said: “Illness and aging affect all our families. With some longer term, moonshot thinking around healthcare and biotechnology, I believe we can improve millions of lives.
“It’s impossible to imagine anyone better than [Levinson] - one of the leading scientists, entrepreneurs and CEOs of our generation - to take this new venture forward.”
Levinson said: “I’ve devoted much of my life to science and technology, with the goal of improving human health. Larry’s focus on outsized improvements has inspired me, and I’m tremendously excited about what’s next.”
Writing on his Google + page Levinson added: “When I served on Google’s board, and I got to know each other well - and when he and Bill Maris approached me about a venture that would take the long term view on ageing and illness, I was deeply intrigued. For example, what underlies aging? Might there be a direct link between certain diseases and the aging process?
“We agreed that with great people, a strong culture and vision and a healthy disregard for the impossible, we could make progress tackling these questions, and improving people’s lives.”
Google has not yet released detailed information on how this will move forward, how much it would invest in the venture, or what healthcare areas in particular in would focus on.
There is also no mention as yet of what the venture is set to produce in terms of products or services.
But the firm did say that Levinson will remain chairman of Genentech and a director of Roche, which bought the firm in 2009, as well as chairman of Apple.
Commenting on his new role, Franz Humer (pictured), chairman of Roche, said: “[Levinson’s] track record at Genentech has been exemplary, and we see an interesting potential for our companies to work together going forward. We’re delighted he’ll stay on our board.”
Tim Cook, chief executive of Apple, said: “For too many of our friends and family, life has been cut short or the quality of their life is too often lacking. Levinson is one of the crazy ones who thinks it doesn’t have to be this way. There is no one better suited to lead this mission and I am excited to see the results.”
Ben Adams
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- Genentech's Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy
- UCB syncs up with Roche and Genentech in Alzheimer's drug deal worth a potential $2bn+
- Roche's Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer
- Roche's Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3
- Genentech's retiring R&D head to be replaced by MIT executive